TYMS and DPYD polymorphisms in a Turkish population

  • H. S. SüzenEmail author
  • N. Yüce
  • G. Güvenç
  • Y. Duydu
  • T. Erke



The thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) enzymes affect the outcome of 5-fluorouracil (5-FU)-based chemotherapy. Genetic polymorphisms of the thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) genes that may affect chemotherapy are described. The aim of this study was to determine the frequencies of TYMS and DPYD polymorphisms in healthy Turkish individuals.


Genotyping analyses of the promoter enhancer region of TYMS (TSER) and the exon 14-skipping mutation of the DPYD (DPYD*2A) genes were conducted in 250 unrelated, healthy volunteers from the central region of Turkey using a PCR-based assay.


The distribution of theTSER*2/*2, *2/*3 and *3/*3 genotypes were 17.6%, 48.8%, and 33.6%, respectively. The frequencies of the TSER*2 and *3 alleles in the Turkish population were 0.42 and 0.58, respectively. No individuals with the variant DPYD*2A allele were identified in the study group.


The frequency of the TSER*3 allele among members of the Turkish population was similar to frequencies observed in other Caucasian populations but was lower than those found in Japanese and Chinese populations.


TYMS DPYD Polymorphism Turkish 



This work was supported by a grant from the Ankara University, Institute of Biotechnology, Project No: 2001-K-120-240.


  1. 1.
    Kawakami K (2004) Thymidylate synthase gene in pharmacogenetics. Curr Pharmacogenomics 2:137–147CrossRefGoogle Scholar
  2. 2.
    Horie N, Aiba H, Ogura K, Hojo H, Takeishi K (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal region of the human gene for thymidylate synthase. Cell Struct Func 20:191–197CrossRefGoogle Scholar
  3. 3.
    Marsh S, Collie-Duguid ESR, Li T, Liu X, McLeod HL (1999) Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58:310–312CrossRefPubMedGoogle Scholar
  4. 4.
    Marsh S, Ameyaw MM, Githang’a J, Indalo A, Ofori-Adjei D, McLeod HL (2000) Novel thymidylate synthase enhancer region alleles in African populations. Hum Mut 16:528–533CrossRefPubMedGoogle Scholar
  5. 5.
    Pullakart ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ (2001) Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1:65–70PubMedGoogle Scholar
  6. 6.
    Villafranca E, Okruzhnov Y, Dominguez MA et al (2001) Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancers. J Clin Oncol 19:1779–1786PubMedGoogle Scholar
  7. 7.
    Diasio RB, Johnson MR (2000) The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-FU. Pharmacology 61:199–203CrossRefPubMedGoogle Scholar
  8. 8.
    McMurrough J, McLeod HL (1996) Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 41:425–427CrossRefPubMedGoogle Scholar
  9. 9.
    Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F, Milano G. (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12:2248–2253PubMedGoogle Scholar
  10. 10.
    Wei X, Elizondo G, Sapone A, McLeod HL, Raunino H, Fernandoz-Salguero P, Gonzalez FJ (1998) Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51:391–400CrossRefPubMedGoogle Scholar
  11. 11.
    van Kuilenburg ABP (2004) Dihydropyrimidine dehydrogenase and efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939–950PubMedCrossRefGoogle Scholar
  12. 12.
    Raida M, Schwabe W, Hausler P, van Kuilenburg ABP, van Gennip AH, Behnke D, Hoffken D (2001) Prevalence of common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with contols. Clin Cancer Res 7: 2832–2839PubMedGoogle Scholar
  13. 13.
    van Kuilenburg ABP, Vreken P, Abeling NGGM et al (1999) Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 104:1–9PubMedCrossRefGoogle Scholar
  14. 14.
    van Kuilenburg ABP, Meinsma JR, Zoetekouw L, van Gennip AH (2002) High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12:555–558PubMedCrossRefGoogle Scholar
  15. 15.
    Johnson MR, Hageboutros A, Wang K, Hish L, Smith JB, Diasio RB (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient following treatment with topical 5-fluorouracil. Clin Cancer Res 5:2006–2011PubMedGoogle Scholar
  16. 16.
    Johnson MR, Diasio R (2001) Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 41:151–157CrossRefPubMedGoogle Scholar
  17. 17.
    Morrison GB, Bastianm A, Dela-Rosa T, Diasio RB, Takimoto CH (1997) Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe advers reactions to 5-fluorouracil based chemotherapy. Oncol Nursing Forum 24:83–88Google Scholar
  18. 18.
    van Kuilenburg ABP, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH (2001) Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 7:1149–1153PubMedGoogle Scholar
  19. 19.
    Efferth T, Volm M (2005) Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 107:155–176CrossRefPubMedGoogle Scholar
  20. 20.
    Lee W, Lockhart AC, Kim RB, Rothenberg ML (2005) Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10:104–111CrossRefPubMedGoogle Scholar
  21. 21.
    Marsh S, McLeod HL (2004) Cancer pharmacogenetics. Br J Cancer 90:8–11CrossRefPubMedGoogle Scholar
  22. 22.
    Robert J, Le Morvan V, Smith D, Pourquier P, Bonnet J (2005) Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 54:171–196PubMedCrossRefGoogle Scholar
  23. 23.
    Sekine I, Saijo N (2001) Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Ann Oncol 12:1515–1525CrossRefPubMedGoogle Scholar
  24. 24.
    Smith NF, Figg WD, Sparreboom A (2004) Recent advances in pharmacogenetic approaches to anticancer drug development. Drug Dev Res 62:233–253CrossRefGoogle Scholar
  25. 25.
    Yamayoshi Y, Iida E, Tanigawara Y (2005) Cancer pharmacogenomics : international trends. Int J Clin Oncol 10:5–13CrossRefPubMedGoogle Scholar
  26. 26.
    Spear BB, Heath-Chiozzi M, Huff J (2001) Clinical application of pharmacogenetics. Trends Mol Med 7:201–204PubMedCrossRefGoogle Scholar
  27. 27.
    Wei X, McLeod HL, NcMurrough J, Gonzalez FJ, Fernandez-Salguero P (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouraci toxicity. J Clin Invest 98:610–615PubMedCrossRefGoogle Scholar
  28. 28.
    Adleef V, Hitre E, Köves I, Orosz Z, Hajnal A, Kralovanszky J (2004) Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients. Int J Cancer 108:852–856CrossRefPubMedGoogle Scholar
  29. 29.
    Hishida A, Matsuo K, Hamajima N, Ito H, Ogura M, Kagami Y, Taji H, Morishima Y, Emi N, Tajima K (2003) Associations between polymorphisms in the thymidylate synthase and serine hydroxymethylytransferase genes and susceptibility to malignant lymphoma. Haematologica 88:159–166PubMedGoogle Scholar
  30. 30.
    Trinh BN, Ong CN, Coetzee GA, Yu MC, Laird PW (2002) Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. Hum Genet 111:299–302CrossRefPubMedGoogle Scholar
  31. 31.
    Luo HR, Lü XM, Yao YG, Horie N, Takeishi K, Jorde LB, Zhang YP (2002) Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem Genet 40:41–51CrossRefPubMedGoogle Scholar
  32. 32.
    Brown KS, Kluijtmans LAJ, Young IS, McNulty H, Mitchell LE et al (2004) The thymidylate synthase tandem repeat polymorphism is not associated with homocysteine concentrations in healthy young subjects. Hum Genet 114:182–185CrossRefPubMedGoogle Scholar
  33. 33.
    Celik I, Kars A, Guc D, Tekuzman G, Ruacan S (2002) Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. Cancer Invest 20:333–339CrossRefPubMedGoogle Scholar
  34. 34.
    Nauck M, Gierens H, Marz W, Wieland H (2001) Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes. Clin Biochem 34:103–105PubMedCrossRefGoogle Scholar
  35. 35.
    Hsiao HH, Yang MY, Chang JG, Liu YC, Liu TC, Chang CS, Chen TP, Lin SF (2004) Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother Pharmacol 54:445–451CrossRefGoogle Scholar
  36. 36.
    Yamaguchi K, Arai Y, Kanda Y, Akagi K (2001) Germline mutation of dihydropyrimidine dehydrogenase gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Can Res 92:337–342Google Scholar
  37. 37.
    Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MSE, Mizugaki M (2002) Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53:596–603CrossRefPubMedGoogle Scholar
  38. 38.
    Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, Fernandez-Salguero PM, Gonzalez FJ, Vreken P, van Kuilenburg ABP, van Gennip AH, Mcleod HL (1998) Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 46:151–156CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • H. S. Süzen
    • 1
    Email author
  • N. Yüce
    • 1
  • G. Güvenç
    • 2
  • Y. Duydu
    • 1
  • T. Erke
    • 3
  1. 1.Department of Toxicology, Faculty of PharmacyAnkara UniversityTandoğan, AnkaraTurkey
  2. 2.Institute of BiotechnologyAnkara UniversityBesevler, AnkaraTurkey
  3. 3.Blood Bank and Transfusion CentreBayindir HospitalSöğütözü, AnkaraTurkey

Personalised recommendations